Mechanisms allowing protein delivery in ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles
Auteur(s) :
Bernocchi, Beatrice [Auteur]
Carpentier, Rodolphe [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lantier, Isabelle [Auteur]
Ducournau, Celine [Auteur]
Dimier-Poisson, Isabelle [Auteur]
Betbeder, Didier [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Carpentier, Rodolphe [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lantier, Isabelle [Auteur]
Ducournau, Celine [Auteur]
Dimier-Poisson, Isabelle [Auteur]
Betbeder, Didier [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Titre de la revue :
Journal of controlled release . official journal of the Controlled Release Society
Nom court de la revue :
J. Control. Release
Numéro :
232
Pagination :
42-50
Date de publication :
2016-06-28
ISSN :
0168-3659
Mot(s)-clé(s) en anglais :
Vaccine
Biodistribution
Transcytosis
Protein delivery
Intranasal drug delivery
Nanoparticle
Biodistribution
Transcytosis
Protein delivery
Intranasal drug delivery
Nanoparticle
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The intranasal administration of proteins using nanoparticles is a promising approach for several applications, especially for mucosal vaccines. Delivery of protein within the epithelial barrier is a key point to elicit ...
Lire la suite >The intranasal administration of proteins using nanoparticles is a promising approach for several applications, especially for mucosal vaccines. Delivery of protein within the epithelial barrier is a key point to elicit an immune response and nano-carrier has to show no toxicity. The aim of this work was to elucidate the interactions of cationic porous nanoparticles loaded with protein delivery for antigen delivery in the nose. We investigated the loading, the cellular delivery and the epithelial transcytosis of proteins associated to these nanoparticles containing an anionic lipid in their core (NPL). NPL were highly endocytosed by airway epithelial cells and significantly improved the protein delivery into the cell. In vitro transcytosis studies showed that NPL did not modify the in vitro epithelial permeability suggesting no toxicity of these carriers. Moreover protein and NPL did not translocate the epithelial barrier. In vivo studies demonstrated that NPL prolonged the nasal residence time of the protein and no NPL were found beyond the epithelial barrier in vivo, precluding a negative side effect. All together these results establish the NPL as a bio-eliminable and optimal vaccine carrier.Lire moins >
Lire la suite >The intranasal administration of proteins using nanoparticles is a promising approach for several applications, especially for mucosal vaccines. Delivery of protein within the epithelial barrier is a key point to elicit an immune response and nano-carrier has to show no toxicity. The aim of this work was to elucidate the interactions of cationic porous nanoparticles loaded with protein delivery for antigen delivery in the nose. We investigated the loading, the cellular delivery and the epithelial transcytosis of proteins associated to these nanoparticles containing an anionic lipid in their core (NPL). NPL were highly endocytosed by airway epithelial cells and significantly improved the protein delivery into the cell. In vitro transcytosis studies showed that NPL did not modify the in vitro epithelial permeability suggesting no toxicity of these carriers. Moreover protein and NPL did not translocate the epithelial barrier. In vivo studies demonstrated that NPL prolonged the nasal residence time of the protein and no NPL were found beyond the epithelial barrier in vivo, precluding a negative side effect. All together these results establish the NPL as a bio-eliminable and optimal vaccine carrier.Lire moins >
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Équipe(s) de recherche :
Therapeutic innovation targetting inflammation
Date de dépôt :
2019-05-17T13:14:39Z